Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilzemetkib + Gemcitabine in Advanced Pancreatic Cancer
NCT06278493Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vilzemetkib in pancreatic cancer (PC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 4 weeks. Started Aug 2018; status: completed.
02
Drugs
vilzemetkib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06278493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278493.